Datapoint: FDA Approves Bristol Myers Squibb’s Breyanzi

After a series of regulatory and manufacturing delays, the FDA last week approved Bristol Myers Squibb’s CAR-T drug Breyanzi for the treatment of large B-cell lymphoma in patients who have not responded to or relapsed following other systemic treatments. Two other CAR-T therapies, Novartis’s Kymriah and Gilead’s Yescarta, are approved for the treatment of large B-cell lymphoma. Under the pharmacy benefit, Kymriah and Yescarta both hold preferred status for 9% of all covered lives.

SOURCE: MMIT Analytics, as of 2/8/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 11

Datapoint: Sentara to Open Community Care Centers, Launch New Model

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today